Skip to content
← Full study record

NCT00873093 · OUTCOME

Toxic Death Rate

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma · Source last updated 2017-01-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
4 months

What was measured

The proportion of toxic death rate among all eligible patients.

Analysis population: The toxic death was monitored for all eligible patients. It was not compared between subgroups per protocol 9.3.2.

Groups in this outcome

Overall

All enrolled eligible patients.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Overall146

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Overall2.1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2.1
denoms
  1. counts
    1. group Id
      OG000
      value
      146
    units
    Participants
description
The proportion of toxic death rate among all eligible patients.
groups
  1. description
    All enrolled eligible patients.
    id
    OG000
    title
    Overall
param Type
NUMBER
population Description
The toxic death was monitored for all eligible patients. It was not compared between subgroups per protocol 9.3.2.
reporting Status
POSTED
time Frame
4 months
title
Toxic Death Rate
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice